List view / Grid view
23 May 2006 | By EPR
Protein crystallography has a key role to play in a project that is making a significant contribution to understanding human diseases. The Structural Genomics Consortium (SGC) has already achieved one landmark, and looks set to continue in a similar vein. Tim Lloyd spoke with Alexey Bochkarev Ph.D., Principal Investigator, Crystallography,…
23 May 2006 | By Carl-Fredrik Mandenius, Linköping University, Sweden, Member of the European Federation for Pharmaceutical Sciences PAT Steering Group
Product quality of pharmaceuticals manufactured in biotechnology processes is to a large extent synonymous with the reduction and control of unwanted biological side-products. Production of biopharmaceutical proteins and secondary metabolites such as antibiotics are the result of biosynthetic capacity of the microbes or cells used. But this capacity may also…
24 March 2006 | By Charanya Ramachandran, Research Analyst, Drug Discovery Technologies, Frost & Sullivan Healthcare (EMEA)
Molecular technologies such as genomics and proteomics have brought in a thorough make-over to early stage drug discovery. The strategic spotlight from the genomics technologies has gradually shifted focus to the cellular domain where the entire drug target interaction takes place. As a result, cell based screening provides promising potential…
24 March 2006 | By Cees Gooijer, Freek Ariese and Reyer J. Dijkstra, Dept. of Analytical Chemistry and Applied Spectroscopy, Laser Centre Vrije Universiteit
Currently, Raman spectroscopy (RS) is rapidly becoming a mature analytical technique in the pharmaceutical world. Thus far, it is used almost exclusively in a stand-alone mode, since coupling with liquid separation methods hardly seemed realistic in practice. However, as outlined in this article, recent developments are quite promising and such…
24 March 2006 | By Dr. Manuela Scholz, Leiter der Herstellung (Product Supply Release Responsible), Procter & Gamble Pharmaceuticals
Due to the need for improvement in the cost structure and efficiency of the pharmaceutical industry, the introduction of NIR analytical techniques in combination with PAT applications is a promising opportunity for cycle time reduction and machine utilisation increase.
2 February 2006 | By Quan Du, Institute of Molecular Medicine, Peking University, Meihong Chen, Chinese Human Genome Center Beijing, Claes Wahlestedt, Scripps Florida and Zicai Liang, Karolinska Institute
Although synthetic siRNA libraries are becoming more available, most high throughput siRNA library-based screening was carried out with siRNA libraries encoded by different vectors. In this article, siRNA library construction methods and HTS applications are summarised.
2 February 2006 | By Carmel B. Nanthakumar, Senior Research Scientist – Automated Imaging and Electrophysiology, Neuroscience Research Centre, Merck Sharp and Dohme
HCS has been implemented as a key technology to address complex biology associated with CNS drug targets. This review will describe a new generation of HCS assays including multiplexed HCS assays with biochemical markers, novel techniques for studying receptor internalisation and the application of HCS to neural network cultures that…
2 February 2006 | By Professor David Littlejohn, Head of the Department of Pure and Applied Chemistry at the University of Strathclyde, Director of CPACT at the University of Strathclyde
There can be no doubt that the FDA’s initiative on Process Analytical Technologies (PAT) has had an enormous impact on the pharmaceutical industries. However, the emergence of ’born again‘ PAT devotees in pharma companies has caused mild amusement in other industries where on-line analysis has been an integral part of…
2 February 2006 | By Elisabeth Pook, Stefan Martin Mundt, Adrian Tersteegen, Department of Cardiovascular Research, Pharma Research Center Wuppertal, Bayer HealthCare AG
Ultra high-throughput screening (UHTS) offers the possibility to discover novel pharmacophores. To benefit from UHTS special demands concerning assay quality and data analysis have to be met.
11 November 2005 | By Dr Frank Straube, Biomarker Expert, Novartis Pharma AG
High content imaging (HCI), the combination of automated fluorescence microscopy with quantitative image analysis, has been opening new dimensions in cytometry. This article gives an overview on the growing spectrum of applications and an outlook on the future use of this still rapidly developing technology.
11 November 2005 | By Steve Doherty and Aaron Garrett, Manufacturing Science and Technology, Mark LaPack, Process Research and Development, Eli Lilly and Co.
Optical techniques can not address every application need, so the well-equipped PAT toolbox must include a broad array of technologies. One analytical tool that has been less-published but no less useful than the optical methods is mass spectrometry. This article provides a brief review of some of the published uses…
Raman spectroscopy is a highly versatile tool that provides chemical fingerprints from biological material that can be interpreted using chemometrics and machine learning. In combination this powerful approach is being developed for the quantitative determination of multiple determinands in bioprocesses and for the characterisation of microorganisms.
11 November 2005 | By Dr Paul G. Royall, Lecturer in Pharmaceutics, School of Chemical Sciences & Pharmacy University of East Anglia, See-wah Jai Tang, Pharmaceutical Science Research Division, King’s College London
Thermal analysis equipment can be found in nearly all of the analytical, development, formulation and QA laboratories within the pharmaceutical industry. However, these work horse instruments are learning to run faster and to analyse an ever more varied field of samples.
22 August 2005 | By Dr Dalin Nie, Associate Director, and Deborah S. Hartman, Director, Lead Discovery, AstraZeneca Pharmaceuticals, Wilmington
Compound management is an emerging discipline that represents a core component of the drug discovery process, from early phases involving high throughput screening (HTS) to late-stage lead optimisation screening cascades.
22 August 2005 | By Stefan Prechtl, Group Leader, High Content Analysis and Philip Denner, Schering AG
High-Content Analysis (HCA) provides a drug discovery tool capable of rapid screening of drug effects in pharmacologically relevant cell culture systems. Interest in HCA has been increasing during the past few years. This reflects the confidence that HCA-technology has established due to the stability and reliability offered to the drug…
